TOKYO, JAPAN – December 6, 2022 – Terumo Corporation today announced the launch of a drug-device combination product co-developed with Kyowa Kirin Co., Ltd., bringing a new treatment option to patients in Japan.
The collaboration combines Terumo's device development and manufacturing expertise with Kyowa Kirin's pharmaceutical research capabilities, resulting in an integrated drug-device combination product designed to improve treatment delivery for patients.
"This launch reflects the value of combining our respective strengths in device technology and pharmaceutical development," said a Terumo representative. "We are pleased to bring this collaborative innovation to patients in Japan and look forward to continued partnership with Kyowa Kirin."
The product is now available to patients in Japan, representing a successful collaboration between the two companies in bringing combination therapies to market.
About Terumo
Terumo (TSE: 4543) is a leading global provider of medical products and solutions with net sales of 4 billion USD. Founded in 1921, Terumo employs over 30,000 associates worldwide, and its products and services are available in more than 160 countries and regions. Terumo's stated mission is "Contributing to Society through Healthcare."
